High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low‐dose methotrexate
- 5 June 2002
- journal article
- clinical trial
- Published by Wiley in Arthritis Care & Research
- Vol. 47 (3) , 326-332
- https://doi.org/10.1002/art.10459
Abstract
Objective To examine the long‐term efficacy of low‐dose intravenous methotrexate (MTX) with and without concomitant glucocorticoids (GC) for remission maintenance in patients with generalized Wegener's granulomatosis (WG) in an open‐label, prospective, standardized trial. Methods After induction of remission by cyclophosphamide and GC, 71 patients (41 males, 30 female) with initially generalized WG received low‐dose methotrexate at 0.3 mg/kg body weight once weekly. At study‐start 55 of 71 (77.5%) patients were on low‐dose GC (mean 5.9 mg/day) which was tapered during the study. All patients underwent interdisciplinary staging at 3‐month (and later at 6‐month) intervals to assess disease activity and extent as well as side effects. End points were the first relapse or the end of study (January 2001). Results Within a mean followup period of 25.2 months, 26 patients (36.6%) experienced a relapse after a mean of 19.4 months. Seventeen (65.4%) of these 26 patients had terminated GC therapy at the time of relapse. There was no difference in relapse rates among patients with and without concomitant GC at study start. Relapses occurred mainly in the initially involved organ systems, preferentially in the ear, nose and throat tract in 18 of 26 patients and the kidney in 16 of 26 patients. One renal relapse presented as rapid, progressive glomerulonephritis with lethal outcome. Further, 14 relapses were accompanied by a significant rise in creatinine values. In 15/26 patients the relapse was paralleled or preceded by a significant rise of antineutrophil cytoplasmic antibody titer. Two patients ceased MTX prematurely because of persistent leukopenia. Conclusion Weekly MTX is a well tolerated therapy for long‐term maintenance of remission. However, one‐third of the patients relapsed during ongoing MTX treatment, irrespective of whether they were still receiving GC. Because more than half of the relapses affected the kidney, close monitoring is indispensable.Keywords
This publication has 17 references indexed in Scilit:
- Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis: Long-term renal outcome in patients with glomerulonephritisArthritis & Rheumatism, 2000
- An interdisciplinary approach to the care of patients with Wegener's granulomatosis: Long-term outcome in 155 patientsArthritis & Rheumatism, 2000
- A staged approach to the treatment of Wegener's granulomatosis: Induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenanceArthritis & Rheumatism, 1999
- Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement.Journal of the American Society of Nephrology, 1998
- Treatment of Antineutrophil Cytoplasm Autoantibody-Associated Systemic Vasculitis: Initiatives of the European Community Systemic Vasculitis Clinical Trials Study GroupMayo Clinic Proceedings, 1997
- Therapy for the maintenance of remission in sixty‐five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazoleArthritis & Rheumatism, 1996
- An analysis of forty‐two wegener's granulomatosis patients treated with methotrexate and prednisoneArthritis & Rheumatism, 1995
- The treatment of wegener's granulomatosis with glucocorticoids and methotrexateArthritis & Rheumatism, 1992
- Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 1992
- The American College of Rheumatology 1990 criteria for the classification of wegener's granulomatosisArthritis & Rheumatism, 1990